Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05226507 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

A Phase 1 study of Ovarian Cancer and Advanced Solid Tumor, sponsored by Nuvectis Pharma.

Active
Registry status
Phase 1
Development phase
45
Enrollment target
20
Study locations

NCT05226507 is a Phase 1 study of Ovarian Cancer and Advanced Solid Tumor that is active but no longer recruiting, run by Nuvectis Pharma. The registered enrollment target is 45 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05226507, a Phase 1 study of Ovarian Cancer and Advanced Solid Tumor, is active but no longer recruiting, sponsored by Nuvectis Pharma.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
45 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.

Conditions Studied

Ovarian Cancer Advanced Solid Tumor Ovarian Endometrioid Adenocarcinoma Ovarian Clear Cell Adenocarcinoma Ovarian Clear Cell Carcinoma ARID1A Gene Mutation Ovarian Endometrioid Tumor Ovarian Clear Cell Tumor

Interventions

  • DRUG NXP800

Study Locations (20)

Florida

  • Florida Cancer Specialists South - Fort Myers
  • Mount Sinai Comprehensive Cancer Center - Miami Beach
  • Florida Cancer Specialists Research North - St. Petersburg
  • Florida Cancer Specialists Research East - West Palm Beach

Oklahoma

  • OU Health Stephenson Cancer Center - Oklahoma City
  • Oklahoma Cancer Specialists and Research Institute - Tulsa

Texas

  • Texas Oncology - Fort Worth
  • The University of Texas MD Anderson Cancer Center - Houston

Arizona

  • Honor Health - Phoenix

California

  • UC San Diego Health - Moores Cancer Center - La Jolla

Colorado

  • University of Colorado Cancer Center - Aurora

Connecticut

  • Yale Gynecologic Oncology - New Haven

Iowa

  • University of Iowa - Iowa City

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2021-12-31
Est. Completion 2025-12
Phase Phase 1

Sponsor

Nuvectis Pharma

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05226507

The ClinicalTrials.gov registry entry for NCT05226507 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Nuvectis Pharma, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which NXP800 is the first listed.

NCT05226507 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, Oklahoma, Texas.

Frequently Asked Questions

What is clinical trial NCT05226507 about?

NCT05226507 is a clinical study titled "A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer". The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.

What is the current status of trial NCT05226507?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2021-12-31. Estimated completion is 2025-12.

What conditions does trial NCT05226507 study?

This clinical trial studies the following conditions: Ovarian Cancer, Advanced Solid Tumor, Ovarian Endometrioid Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Clear Cell Carcinoma.

What interventions are being tested in trial NCT05226507?

The interventions under investigation include: NXP800 (DRUG).

Who is sponsoring clinical trial NCT05226507?

This trial is sponsored by Nuvectis Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05226507 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ovarian Cancer

All registered trials for this condition

Advanced Solid Tumor

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.